Business
CANAQUEST MEDICAL CORP announces filing of INTERNATIONAL CANNABIS PATENT
CANAQUEST MEDICAL CORP announces filing of INTERNATIONAL CANNABIS PATENT.
About this update from Canaquest Medical Corporation
[{"type":"text","content":"\n A NOVEL BOTANICAL AND TETRAHYDROCANNABINOL (“THC”) FORMULATION FOR THE REDUCTION OF CANNABIS-INDUCED NEGATIVE NEUROPSYCHIATRIC SIDE-EFFECTS Research & development a primary focus for this medical cannabis company TORONTO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the \"Company\" or “CanaQuest”), a company developing unique health products and nutraceuticals utilizing cannabis and botanical oil extracts, has filed an International Cannabis/Botanical Patent which stems from its sponsored research program at Western University in London, Ontario, Canada. The use of marijuana is known to cause neuronal, molecular and neuropsychiatric side effects. This complicates the use of marijuana for medical treatment. Δ-9-tetrahydrocannabinol (THC) is the primary psychoactive compound in marijuana (MJ). As demonstrated in both clinical and pre-clinical research, THC is associated with a wide range of deleterious neuropsychiatric side-effects in both adolescent and adult users of MJ products. Chronic or acute THC exposure has been shown to increase anxiety, increase depressive symptoms, increase vulnerability to schizophrenia-related symptoms and to produce profound cognitive side effects such as deficits in cognitive filtering and memory impairments. Given the increasing use of ‘medical’ marijuana for the treatment of a wide variety of ailments, there is an urgent need for the development of a safer THC formulation that lacks the neurocognitive and neuropsychiatric side-effects associated with MJ usage. The patented formulated product is called Mentabinol™, which treats various psychiatric disorders. Mentabinol™ – Formulation utilizing Food Grade Botanical Extract “BX” and extracted THC oil from the MJ plant.The application of Mentabinol™ in pre-clinical trials at Western University have demonstrated: Reversal of depression-like and schizophrenia related symptom effects;Complete blockage of memory impairment;Complete blockage of hyperactive activity;Complete blockage of gene vulnerability. The discovery was made by a research team led by Dr. Steven Laviolette, the scientist at Western University in charge of one of the two sponsored research programs that CanaQuest currently has with prominent Canadian univers...